The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Unmet needs in myelofibrosis and future outlooks
Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses unmet needs in myelofibrosis (MF) and how the field has progressed in recent years. First, Dr Bose highlights three major unmet needs in MF: cytopenias, the need to improve approaches after failure of JAK inhibitors, and the need to improve combination approaches with JAK inhibitors. Dr Bose then comments on exciting novel agents and their role in the future of MF treatment. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research support: Incyte, BMS, CTI BioPharma, Kartos, Morphosys, Blueprint Medicines, Cogent, IONIS, Astellas, Pfizer, NS Pharma, Promedior.
Honoraria: Incyte, BMS, CTI BioPharma, Kartos, Morphosys, Blueprint Medicines, Cogent, Abbvie, Sierra Oncology (now GSK), Karyopharm, Pharma Essentia, Novartis.
